Prothena | PRTA - Equity Capital And Reserves


Prothena reported $286.89M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Akebia Therapeutics USD 25.02M 2.36M Jun/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Exelixis USD 1.84B 91.99M Jun/2026
Immunic USD 151.23M 157.91M Mar/2026
Incyte USD 6.34B 721.58M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Prothena USD 286.89M 25.72M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026